Non-Clear Cell Renal Cell Carcinoma: Does the Mammalian Target of
Rapamycin Represent a Rational Therapeutic Target?

LAURENCE ALBIGES, VINCENT MOLINIE, BERNARD ESCUDIER

The Oncologist 2012;17:1051–1062; doi: 10.1634/theoncologist.2012-0038

In Table 3, the sponsor and clinicaltrials.gov identifier for the ASPEN trial were misidentified. In addition, on page 1058, the identifier for this trial is incorrect. The identifier is NCT01108445 and the sponsor is Duke University. The publisher regrets these errors.